<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nid</journal-id><journal-title-group><journal-title xml:lang="ru">Нефрология и диализ</journal-title><trans-title-group xml:lang="en"><trans-title>Nephrology and Dialysis</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1680-4422</issn><issn pub-type="epub">2618-9801</issn><publisher><publisher-name>Российское диализное общество</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.28996/2618-9801-2020-1-84-92</article-id><article-id custom-type="elpub" pub-id-type="custom">nid-197</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Маркеры системного воспаления как предикторы тяжести типичного гемолитико-уремического синдрома у детей</article-title><trans-title-group xml:lang="en"><trans-title>Markers of systemic inflammation as predictors of the severity of typical hemolytic uremic syndrome in children</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Панкратенко</surname><given-names>Т. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Pankratenko</surname><given-names>T. E.</given-names></name></name-alternatives><email xlink:type="simple">t.pankratenko@inbox.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Москалец</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Moskalets</surname><given-names>O. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Центр гравитационной хирургии крови и гемодиализа ГБУЗ «Детская городская клиническая больница Св. Владимира ДЗМ»; Кафедра трансплантологии, нефрологии и искусственных органов ГБУЗ МО «Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Сenter of gravitational blood surgery and hemodialysis, St. Vladimir’s Children's City Clinical Hospital; Department of Transplantology, Nephrology and Artificial Organs, Moscow Regional Research and Clinical Institute (MONIKI)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Научно-исследовательская лаборатория ГБУЗ МО «Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Research laboratory, Moscow Regional Research and Clinical Institute (MONIKI)</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>26</day><month>07</month><year>2024</year></pub-date><volume>22</volume><issue>1</issue><fpage>84</fpage><lpage>92</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Панкратенко Т.Е., Москалец О.В., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Панкратенко Т.Е., Москалец О.В.</copyright-holder><copyright-holder xml:lang="en">Pankratenko T.E., Moskalets O.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.nephro.ru/jour/article/view/197">https://journal.nephro.ru/jour/article/view/197</self-uri><abstract><p>Типичный гемолитико-уремический синдром (тГУС) - тяжелое заболевание из группы тромботических микроангиопатий, патогенез которого связан с повреждением эндотелия, обусловленным действием шига-токсина (Stx) и выбросом провоспалительных и просклеротических цитокинов активированными лейкоцитами и макрофагами. Маркеры системного воспаления, в частности, провоспалительные цитокины и их растворимые рецепторы, могут обладать прогностической ценностью при тГУС как предикторы тяжести заболевания. Цель исследования: определение сывороточных концентраций ФНОα и рФНОα, ИЛ-6 и рИЛ-6, ИЛ-10 у детей в острой фазе тГУС, а также оценка их информативности как маркеров тяжести и длительности заболевания. Материалы и методы: сывороточная концентрация вышеуказанных цитокинов и их рецепторов была исследована методом твердофазного иммуноферментного анализа у 30 пациентов в острой фазе тГУС на 2-4 сутки заболевания. Группу сравнения составил 21 ребенок в катамнезе тГУС. Результаты: сывороточная концентрация ФНОα и рФНОα, ИЛ-6 и рИЛ-6, ИЛ-10 у детей в острой фазе тГУС была достоверно выше, чем в группе катамнеза. В подгруппе больных с тяжелым течением тГУС была достоверно выше сывороточная концентрация ИЛ-6, а также лейкоцитоз, сывороточная концентрация СРБ и ЛДГ, ниже уровень компонента комплемента С3. Выявлена статистически значимая связь с неблагоприятным течением тГУС лейкоцитоза более 13,5×109/л (ОШ 13,75, 95% ДИ 1,45-130,25), уровня СРБ &gt;9 мг/л (ОШ 7,80, 95% ДИ 1,48-41,22), снижения С3 &lt;90 мг/л (ОШ 28,60, 95% ДИ 2,89-283,07), а также повышения уровня какого-либо из цитокинов ИЛ-6, ИЛ-10, рФНО (ОШ 7,86, 95% ДИ 1,41-47,04). Заключение: выраженный лейкоцитоз и повышенный уровень СРБ, низкий уровень С3, а также повышение уровня ИЛ-6 и/или ИЛ-10 и/или рФНОα у пациентов с тГУС было статистически значимо связано с тяжелым течением заболевания, что позволяет рассматривать эти факторы в качестве предикторов тяжести тГУС.</p></abstract><trans-abstract xml:lang="en"><p>Typical hemolytic-uremic syndrome is a severe disease of thrombotic microangiopathies. Its pathogenesis is associated with Stx-induced damage to the endothelium and the release of pro-inflammatory and prosclerotic cytokines by activated leukocytes and macrophages. Markers of systemic inflammation, in particular, proinflammatory cytokines and their soluble receptors, may have prognostic value for tHUS as predictors of disease severity. Objective: to determine serum concentrations of TNFα and rTN, IL-6 and rIL-6, IL-10 in children with the acute phase of tHUS and to evaluate their informativeness as predictors of the disease’s severity and duration. Materials and methods: The serum concentration of the above cytokines and their receptors was measured by ELISA in 30 patients in the acute phase of tHUS. The comparison group consisted of 21 children in the follow-up period of tHUS. Results: serum concentration of TNFα and rTNF, IL-6 and rIL-6, IL-10 was significantly higher in children with acute-phase tHUS than in the follow-up group. In the subgroup of patients with severe tHUS, the serum concentration of IL-6 was significantly higher, as well as leukocytosis, the serum concentration of CRP and LDH, and the level of complement component C3 was lower. A statistically significant relationship with tHUS course was found for leukocytosis more than 13.5×109/L (OR 13.75, 95% CI 1.45-130.25), CRP level &gt;9 mg/L (OR 7.80, 95% CI 1.48-41.22), a decrease in C3 &lt;90 mg/L (OR 28.60, 95% CI 2.89-283.07), as well as increase in the level of any of the cytokines IL-6, IL-10, rTNF (OR 7.86, 95% CI 1.41-47.04). Conclusion: prominent leukocytosis and increased CRP level, low C3 level, as well as increased levels of IL-6 and/or IL-10 and / or rTNF in patients with tHUS were statistically significantly associated with the severe course of the disease, which allows us to consider these factors as predictors of the severity of tHUS.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>гемолитико-уремический синдром</kwd><kwd>дети</kwd><kwd>интерлейкин-6</kwd><kwd>интерлейкин-10</kwd><kwd>фактор некроза опухоли альфа</kwd><kwd>hemolityc-uremic syndrome</kwd><kwd>children</kwd><kwd>interleukin-6</kwd><kwd>interleukin-10</kwd><kwd>tumor necrosis factor alfa</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Эмирова Х.М., Толстова Е.М., Каган М.Ю. и др. Гемолитико-уремический синдром, ассоциированный с шига-токсин продуцирующей Escherichia coli.Нефрология; 2016; 20(2):18-32.</mixed-citation><mixed-citation xml:lang="en">Эмирова Х.М., Толстова Е.М., Каган М.Ю. и др. Гемолитико-уремический синдром, ассоциированный с шига-токсин продуцирующей Escherichia coli.Нефрология; 2016; 20(2):18-32.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Bnyand M, Mariani-Kurkjian P, Gouali M et al. Hemolitic uremic syndrome due to Shiga toxin-producing Escherichia coli infection. Médecine et maladies infectieuses. 2018; 48: 167-174</mixed-citation><mixed-citation xml:lang="en">Bnyand M, Mariani-Kurkjian P, Gouali M et al. Hemolitic uremic syndrome due to Shiga toxin-producing Escherichia coli infection. Médecine et maladies infectieuses. 2018; 48: 167-174</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ardissino G, Dacco V, Testa S et al. Hemoconcentration: a majo rrisk factorfor neurological involvement in hemolytic uremic syndrome. Pediatr Nephrol. 2015; 30(2): 345-52.</mixed-citation><mixed-citation xml:lang="en">Ardissino G, Dacco V, Testa S et al. Hemoconcentration: a majo rrisk factorfor neurological involvement in hemolytic uremic syndrome. Pediatr Nephrol. 2015; 30(2): 345-52.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Ardissino G, Tel F, Possenti I, Testa S et al. Early volume expansion and outcomes of hemolytic uremic syndrome. Pediatrics. 2016; 137(1): e20152153</mixed-citation><mixed-citation xml:lang="en">Ardissino G, Tel F, Possenti I, Testa S et al. Early volume expansion and outcomes of hemolytic uremic syndrome. Pediatrics. 2016; 137(1): e20152153</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Панкратенко Т.Е., Москалец О.В., Абасеева Т.Ю. Клинико-диагностическое значение определения растворимых молекул адгезии sICAM и sVCAM у детей с типичным гемолитико-уремическим синдромом. Вопросы практической педиатрии; 2017; 12(4): 7-14.</mixed-citation><mixed-citation xml:lang="en">Панкратенко Т.Е., Москалец О.В., Абасеева Т.Ю. Клинико-диагностическое значение определения растворимых молекул адгезии sICAM и sVCAM у детей с типичным гемолитико-уремическим синдромом. Вопросы практической педиатрии; 2017; 12(4): 7-14.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Палеев Ф.Н., Белокопытова И.С., Минченко Б.И., Москалец О.В. Роль цитокинов в патогенезе ишемической болезни сердца. Креативная кардиология. 2011; 1: 75-80.</mixed-citation><mixed-citation xml:lang="en">Палеев Ф.Н., Белокопытова И.С., Минченко Б.И., Москалец О.В. Роль цитокинов в патогенезе ишемической болезни сердца. Креативная кардиология. 2011; 1: 75-80.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Cимбирцев А.С. Цитокины в патогенезе и лечении заболеваний человека. - Монография. СПб.:Фолиант. 2018. 512 с.</mixed-citation><mixed-citation xml:lang="en">Cимбирцев А.С. Цитокины в патогенезе и лечении заболеваний человека. - Монография. СПб.:Фолиант. 2018. 512 с.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Moake J. Thrombotic Microangiopathies: Multimers, Metalloprotease, and Beyond. Clin Transl Sci. 2009 Oct; 2(5): 366-373.</mixed-citation><mixed-citation xml:lang="en">Moake J. Thrombotic Microangiopathies: Multimers, Metalloprotease, and Beyond. Clin Transl Sci. 2009 Oct; 2(5): 366-373.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Brandelli JR, Griener TP, Laing A et al. The effects of Shiga toxin 1, 2 and their subunits on cytokine and chemokine expression by human macrophage-like THP-1 cells toxins (Basel). 2015; 7(10): 4054-4066.</mixed-citation><mixed-citation xml:lang="en">Brandelli JR, Griener TP, Laing A et al. The effects of Shiga toxin 1, 2 and their subunits on cytokine and chemokine expression by human macrophage-like THP-1 cells toxins (Basel). 2015; 7(10): 4054-4066.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Brigotti M, Carnicelli D, Arfilli V et al. Human monocytes stimulated by Shiga toxin 1a via globotriaosylceramide release proinflammatory molecules associated with hemolytic uremic syndrome. Int J Med Microbiol. 2018; 308(7):940-946.</mixed-citation><mixed-citation xml:lang="en">Brigotti M, Carnicelli D, Arfilli V et al. Human monocytes stimulated by Shiga toxin 1a via globotriaosylceramide release proinflammatory molecules associated with hemolytic uremic syndrome. Int J Med Microbiol. 2018; 308(7):940-946.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Ledesma MA, Ochoa SA, Cruz A et al. The Hemorrhagic Coli Pilus (HCP) of Escherichia coli O157:H7 Is an Inducer of Proinflammatory Cytokine Secretion in Intestinal Epithelial Cells. 2010; PLoS ONE, DOI: 10.1371/journal.pone.0012127</mixed-citation><mixed-citation xml:lang="en">Ledesma MA, Ochoa SA, Cruz A et al. The Hemorrhagic Coli Pilus (HCP) of Escherichia coli O157:H7 Is an Inducer of Proinflammatory Cytokine Secretion in Intestinal Epithelial Cells. 2010; PLoS ONE, DOI: 10.1371/journal.pone.0012127</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Van der Kar N, Sauerwein R, Demarcker P et al. Plasma cytokine levels in hemolytic uremic syndrome. Nephron 1995; 71: 309-313</mixed-citation><mixed-citation xml:lang="en">Van der Kar N, Sauerwein R, Demarcker P et al. Plasma cytokine levels in hemolytic uremic syndrome. Nephron 1995; 71: 309-313</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Inward C, Varagunam M, Adu D et al. Cytokines in haemolytic uraemic syndrome associated with verocytotoxin-producing Eschrichia coli infection. Archives of Disease in Childhood 1997; 77(2): 145-147</mixed-citation><mixed-citation xml:lang="en">Inward C, Varagunam M, Adu D et al. Cytokines in haemolytic uraemic syndrome associated with verocytotoxin-producing Eschrichia coli infection. Archives of Disease in Childhood 1997; 77(2): 145-147</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Shimizu M, Kuroda M, Sakashita N et al. Cytokine profiles of patients with enterohemorrhagic Escherichia coli O111-induced hemolytic-uremic syndrome. Cytokine. 2012; 60(3): 694-700.</mixed-citation><mixed-citation xml:lang="en">Shimizu M, Kuroda M, Sakashita N et al. Cytokine profiles of patients with enterohemorrhagic Escherichia coli O111-induced hemolytic-uremic syndrome. Cytokine. 2012; 60(3): 694-700.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Shimizu M, Kuroda M, Inoue N et al. Extensive serum biomarker analysis in patients with enterohemorrhagic Escherichia coli O111-induced hemolytic-uremic syndrome. Cytokine. 2014; 66(1): 1-6.</mixed-citation><mixed-citation xml:lang="en">Shimizu M, Kuroda M, Inoue N et al. Extensive serum biomarker analysis in patients with enterohemorrhagic Escherichia coli O111-induced hemolytic-uremic syndrome. Cytokine. 2014; 66(1): 1-6.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Cavaillon JM, Adib-Conquy M, Fitting C et al. Cytokine cascade in sepsis. Scand J Infect Dis. 2003; 35(9): 535-544. DOI: 10.1080/00365540310015935.</mixed-citation><mixed-citation xml:lang="en">Cavaillon JM, Adib-Conquy M, Fitting C et al. Cytokine cascade in sepsis. Scand J Infect Dis. 2003; 35(9): 535-544. DOI: 10.1080/00365540310015935.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Chaundry H, Zhou J, Zhong J et al. Role of Cytokines as a Double-edged Sword in Sepsis. In Vivo. 2013; 27(6): 669-684</mixed-citation><mixed-citation xml:lang="en">Chaundry H, Zhou J, Zhong J et al. Role of Cytokines as a Double-edged Sword in Sepsis. In Vivo. 2013; 27(6): 669-684</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Schulte W, Bernhagen J, Bucala R. Cytokines in Sepsis: Potent Immunoregulators and Potential Therapeutic Targets-An Updated View. Mediators of Inflammation 2013; http://dx.doi.org/10.1155/2013/165974</mixed-citation><mixed-citation xml:lang="en">Schulte W, Bernhagen J, Bucala R. Cytokines in Sepsis: Potent Immunoregulators and Potential Therapeutic Targets-An Updated View. Mediators of Inflammation 2013; http://dx.doi.org/10.1155/2013/165974</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Castillo P, Kolls J K. IL-10: A Paradigm for Counterregulatory Cytokines. J Immunol 2016; 197:1529-1530</mixed-citation><mixed-citation xml:lang="en">Castillo P, Kolls J K. IL-10: A Paradigm for Counterregulatory Cytokines. J Immunol 2016; 197:1529-1530</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Ng PC, Li K, Wong RP et al. Proinflammatory and anti-inflammatory cytokine responses in preterm infants with systemic infections. Arch Dis Child Fetal Neonatal Ed. 2003; 88(3): F209-13</mixed-citation><mixed-citation xml:lang="en">Ng PC, Li K, Wong RP et al. Proinflammatory and anti-inflammatory cytokine responses in preterm infants with systemic infections. Arch Dis Child Fetal Neonatal Ed. 2003; 88(3): F209-13</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Matsumoto Н, Ogura H, Shimizu K et al. The clinical importance of a cytokine network in the acute phase of sepsis. Scientific Reports 2018; 8:13995 DOI:10.1038/s41598-018-32275-8 1</mixed-citation><mixed-citation xml:lang="en">Matsumoto Н, Ogura H, Shimizu K et al. The clinical importance of a cytokine network in the acute phase of sepsis. Scientific Reports 2018; 8:13995 DOI:10.1038/s41598-018-32275-8 1</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Benkoe T, Baumann S, Weninger M et al. Comprehensive evaluation of 11 cytokines in premature infants with surgical necrotizing enterocolitis. PLoS One. 2013; 8(3): e58720.</mixed-citation><mixed-citation xml:lang="en">Benkoe T, Baumann S, Weninger M et al. Comprehensive evaluation of 11 cytokines in premature infants with surgical necrotizing enterocolitis. PLoS One. 2013; 8(3): e58720.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
